AdAlta Finalizes 236 Million Share Placement at $0.004 Each to Sophisticated Investors

AdAlta Completes 236 Million Share Placement Announced in May 2026

AdAlta Limited has officially finalized the issuance of 236,250,012 fully paid ordinary shares as part of a private placement first disclosed on 4 May 2026. The placement was conducted in two parts: 198,750,012 shares were allocated to sophisticated investors, and 37,500,000 shares were issued to the Lead Manager. Both segments were priced uniformly at $0.004 per share.

The company communicated the completion through a cleansing notice dated 2 July 2026, signed by Company Secretary Cameron Jones. This notice complies with statutory requirements under the Corporations Act 2001 and is a standard procedure for placements conducted without a formal prospectus or disclosure document. The cleansing notice enables recipients of placement shares to resell them on the open market without restrictions.

Insights from the $0.004 Share Issue Price on AdAlta's Capital Status

The $0.004 share price reflects AdAlta's status as a micro-cap, early-stage biotechnology company. The 198,750,012 shares issued to sophisticated investors correspond to a gross subscription amount of approximately $795,000, while the 37,500,000 shares allocated to the Lead Manager represent a notional value near $150,000. Together, the placement implies gross proceeds of roughly $945,000. The company has not disclosed net proceeds or exact cash received in this update.

Shares granted to the Lead Manager often serve as remuneration for services related to the placement rather than a cash subscription. AdAlta did not clarify in the cleansing notice whether these shares were issued as fees or for cash. Investors seeking clarity on total cash proceeds should consult the original 4 May 2026 announcement or await future financial disclosures.

Protection for Placement Investors via Section 708A Cleansing Notice

The cleansing notice filed by AdAlta operates under section 708A(5)(e) of the Corporations Act 2001, designed for listed companies issuing shares to sophisticated or professional investors without a Full Disclosure document like a prospectus. Normally, such shares carry resale restrictions to retail investors. The cleansing notice removes these, subject to statutory declarations.

AdAlta confirmed compliance with Chapter 2M of the Corporations Act, covering financial reporting, and sections 674 and 674A, which mandate continuous disclosure. The company also asserted there is no "excluded information"—material information withheld from the market—as defined under sections 708A(7) and 708A(8). These statements confirm the company’s disclosures are current and complete as of 2 July 2026.

Appendix 2A Filing Indicates Imminent Quotation of New Shares

Alongside the cleansing notice, AdAlta noted that Appendix 2A applications for the quotation of the newly issued shares have been separately lodged with ASX. This formal application requests the admission of the 236,250,012 new shares to trading on the ASX platform. Upon approval, these shares will be tradeable alongside existing AdAlta shares.

The timing of quotation depends on ASX processing. Investors should note that these new shares will significantly increase AdAlta's total shares on issue, impacting per-share metrics such as Earnings Per Share and net asset value per share, as well as causing dilution. The company has not disclosed the total shares on issue post-placement in this update.

AdAlta Confirms Compliance with Continuous Disclosure as of 2 July 2026

A key aspect of the cleansing notice is AdAlta’s confirmation of adherence to ASX continuous disclosure obligations under sections 674 and 674A of the Corporations Act. These require immediate disclosure of any information likely to affect the price or value of the company’s securities, barring limited exceptions.

This declaration assures investors that no undisclosed material information exists as of the notice date. Such assurance is vital for placement investors relying on the company’s disclosure integrity. Any future contradictory disclosures could have legal and regulatory consequences.

Lead Manager’s Role in the May 2026 Placement

The placement included 37,500,000 shares issued to the Lead Manager, who typically facilitates the placement by sourcing sophisticated investors, managing the bookbuild, and ensuring regulatory compliance. The Lead Manager’s identity was not restated in the cleansing notice; interested parties should refer to the 4 May 2026 announcement.

Issuing shares to the Lead Manager is common in Australian small-cap capital raises, aligning adviser interests with the raise’s success and reducing upfront cash costs for the company. However, it contributes to dilution for existing shareholders. The company did not disclose terms attached to these shares in this update.

AdAlta’s i-Body Platform and Context for Capital Raising

AdAlta is a clinical-stage biotech company leveraging proprietary i-body technology, inspired by shark antibodies, to develop small, stable proteins targeting challenging molecules. Its lead program focuses on fibrosis and inflammatory diseases. Capital raises like this placement are typical for early-stage biotechs without commercial revenue, funding ongoing research, development, and operations.

While this update does not specify the use of proceeds, prior communications usually outline funding allocation for research and development, regulatory milestones, and corporate expenses. Long-term investors will watch for pipeline progress updates that justify this capital raise. No allocation details were provided here.

Dilution Effects on Existing Shareholders from 236 Million New Shares

The issuance of 236,250,012 shares significantly expands AdAlta’s capital base. The $0.004 issue price aligns with typical micro-cap biotech placements, which often price near market levels to attract investors. The dilution impact depends on the total shares outstanding before this placement, which was not restated in the cleansing notice.

Shareholders assessing dilution should consult AdAlta’s latest Annual Report, quarterly activity report, or Appendix 3B filed with the 4 May 2026 placement announcement. These documents, accessible via the ASX Market Announcements Platform, provide context to calculate the percentage increase in shares outstanding due to this placement.

What AdAlta Investors Should Watch Post-Share Issuance

With the cleansing notice lodged and Appendix 2A applications submitted, the next step is the formal quotation of the 236,250,012 new shares on the ASX. Once trading begins, these shares will be freely tradable by sophisticated investors and the Lead Manager. Market participants will observe whether these shareholders hold or sell their shares, potentially influencing near-term trading in 1AD securities.

Beyond share quotation, investors will seek updates on how the raised capital will be deployed to advance AdAlta’s pipeline. Key milestones to monitor include clinical program progress, partnership or licensing developments, and further capital management decisions. The cleansing notice itself is administrative and did not have an observable immediate impact on the company’s business.